Illumina: Will Its Latest China Partnerships Unlock Its Next Billion-Dollar Market?

Illumina reported a solid financial performance for the third quarter of 2025, riding on the strength of its NovaSeq X transition and robust demand in the clinical markets. The company posted a total revenue of $1.08 billion, which was slightly above expectations. Importantly, revenue outside China saw a 2% year-over-year increase, signaling a return to growth despite ongoing macroeconomic challenges and regulatory roadblocks, particularly in Greater China. The company’s non-GAAP operating margin expanded to 24.5%, showing solid year-over-year improvement, while non-GAAP diluted earnings per share (EPS) rose to $1.34. These figures reflect successful cost management and operational efficiency, allowing for margin expansion even as the company navigates pricing pressures. Illumina’s strategic focus on clinical markets has begun to pay off, highlighted by a high single-digit increase in sequencing consumables revenue within this segment.